Emergent BioSolutions | EBS - Ordinary Share Capital


Emergent BioSolutions reported $100K in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Akebia Therapeutics USD 2K 0 Mar/2025
ALKERMES USD 165.61M 503K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amarin USD 20.8M 28K Sep/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Coherus Biosciences USD 12K 0 Mar/2025
Emergent BioSolutions USD 100K 0 Jun/2023
Exact Sciences USD 189.45M 232K Sep/2025
Exelixis USD 268.1M 2.03M Sep/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Heron Therapeutics USD 1.52M 14K Sep/2024
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Lonza CHF 72M 0 Dec/2024
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Myriad Genetics USD 93.1M 0 Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Pacira USD 41.12M 1.85M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
United Therapeutics USD 43.64M 740K Dec/2025
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Xoma USD 87K 1000 Jun/2024